Valuation: Tenax Therapeutics, Inc.

Market Cap 103M 91.83M 84.47M 76.54M 143M 9.74B 146M 1.01B 404M 5.12B 385M 377M 16.15B P/E 2026 *
-1.23x
P/E 2027 * -1.19x
Enterprise Value -240M -215M -198M -179M -335M -22.79B -341M -2.36B -947M -11.99B -901M -882M -37.81B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.82%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tenax Therapeutics, Inc.

1 day-3.76%
1 week+4.07%
1 month-5.29%
3 months-86.93%
6 months-86.35%
Current year-85.32%
1 week 1.6
Extreme 1.6
2.01
1 month 1.36
Extreme 1.36
2.01
Current year 1.31
Extreme 1.31
19.4
1 year 1.31
Extreme 1.31
19.4
3 years 1.31
Extreme 1.31
61.2
5 years 1.31
Extreme 1.31
2,544
10 years 1.31
Extreme 1.31
84,800
Manager TitleAgeSince
Chief Executive Officer 52 14/07/2021
Director of Finance/CFO 58 11/05/2026
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Chairman 67 01/06/2021
Director/Board Member 76 25/02/2021
Director/Board Member 70 25/02/2021
Date Insider Type Main position Quantity % Market Cap. Importance
16/9/26 Buy

Director

53,000 0.1416%
15/9/26 Buy

Chief Executive Officer

4,850 0.0130%
11/9/26 Buy

Chief Financial Officer

5,675 0.0152%
Change 5-day change 1-year change 3-year change Capi.($)
-3.76%+4.07%-75.61%-87.94% 103M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average -0.07%+7.19%+35.26%+166.69% 39.44B
Weighted average by Cap. +0.18%+5.44%+47.96%+176.60%

Financials

2026 *2027 *
Net sales - -
Net income -72.73M -65.14M -59.92M -54.29M -101M -6.91B -103M -715M -287M -3.63B -273M -267M -11.46B -84.06M -75.29M -69.25M -62.75M -117M -7.98B -119M -826M -332M -4.2B -315M -309M -13.24B
Net Debt -343M -307M -282M -256M -478M -32.53B -487M -3.37B -1.35B -17.11B -1.29B -1.26B -53.96B -10.2M -9.14M -8.4M -7.61M -14.23M -968M -14.5M -100M -40.23M -509M -38.28M -37.47M -1.61B
Projected Income Statement - Annual - Tenax Therapeutics, Inc.
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
30/10/26 US$1.790 -3.76% 888,064
29/10/26 US$1.860 -1.06% 2,459,712
28/10/26 US$1.880 +9.30% 1,656,143
27/10/26 US$1.720 +4.88% 1,672,167
26/10/26 US$1.640 -4.65% 1,264,090
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Tenax Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
1.790USD
Average target price
9.625USD
Spread / Average Target
+437.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Tenax Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. TENX Stock